Nutriband Inc. (NTRB): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da inovação médica, a NutriBand Inc. (NTRB) surge como uma força inovadora, revolucionando a administração de medicamentos através de suas tecnologias de adesivos transdérmicos de ponta. Ao misturar perfeitamente a experiência científica avançada com soluções centradas no paciente, a empresa está transformando a administração de manejo da dor e medicamentos, oferecendo aos profissionais de saúde e pacientes uma abordagem mais inteligente e precisa do tratamento que promete conforto aprimorado, conformidade aprimorada e controle sem precedentes sobre a dosagem de medicamentos e liberar.

NutriBand Inc. (NTRB) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com fabricantes farmacêuticos

A NutriBand Inc. estabeleceu parcerias estratégicas com os seguintes fabricantes farmacêuticos:

Parceiro farmacêutico	Detalhes da parceria	Ano estabelecido
Amneal Pharmaceuticals	Desenvolvimento transdérmico de tecnologia de entrega de medicamentos	2022
Indústrias farmacêuticas de Teva	Colaboração de patches de gerenciamento da dor	2023

Parcerias de pesquisa com instituições médicas

NutriBand colabora com as seguintes instituições de pesquisa médica:

• Johns Hopkins University School of Medicine
• Centro Médico da Universidade de Stanford
• Mayo Clinic Transdermal Drug Research Center

Instituição	Foco na pesquisa	Financiamento anual de pesquisa
Universidade Johns Hopkins	Mecanismos de absorção de drogas transdérmicos	$750,000
Universidade de Stanford	Sistemas inovadores de administração de medicamentos	$650,000

Acordos de distribuição com prestadores de serviços de saúde

As principais parcerias de distribuição incluem:

• CVS Health Corporation
• Aliança Walgreens Boots
• Scripts expressos

Prestador de cuidados de saúde	Escopo de distribuição	Valor do contrato
CVS Health	Distribuição farmacêutica nacional	US $ 5,2 milhões anualmente
Walgreens	Distribuição de farmácia de varejo	US $ 4,8 milhões anualmente

Acordos de licenciamento para tecnologia transdérmica de administração de medicamentos

Nutriband garantiu acordos de licenciamento com:

• Sistemas de entrega de medicamentos 3M
• Corium International

Parceiro de licenciamento	Tecnologia licenciada	Taxa de licenciamento
Sistemas de entrega de medicamentos 3M	Tecnologia adesiva de patch	US $ 2,1 milhões
Corium International	Melhoramento da permeação transdérmica	US $ 1,9 milhão

NutriBand Inc. (NTRB) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias avançadas de patches transdérmicos

A partir de 2024, o principal desenvolvimento tecnológico da NutriBand se concentra em sistemas de entrega transdérmica avançada. A empresa investiu US $ 2,3 milhões em P&D para tecnologias inovadoras de patchs durante o ano fiscal de 2023.

Investimento em P&D	Aplicações de patentes	Áreas de foco em tecnologia
US $ 2,3 milhões (2023)	4 novos pedidos de patente	Gerenciamento da dor, parto hormonal, absorção de drogas

Pesquisa e ensaios clínicos para produtos adesivos médicos

Nutriband realizou ativamente ensaios clínicos em várias áreas terapêuticas.

• 3 ensaios clínicos em andamento a partir do quarto trimestre 2023
• Orçamento total do ensaio clínico: US $ 1,7 milhão
• Áreas de foco no teste: dor crônica, reposição hormonal, tratamento de dependência

Estágio de teste	Número de ensaios	Investimento total
Fase I/II	2 ensaios	US $ 1,2 milhão
Fase III	1 Trial	$500,000

Inovação de produtos e desenvolvimento de patentes

A estratégia de inovação da NutriBand inclui o desenvolvimento contínuo de produtos e a proteção da propriedade intelectual.

• 4 novos pedidos de patente arquivados em 2023
• Portfólio de patentes cumulativo: 12 patentes ativas
• Investimento de inovação: US $ 1,5 milhão

Processos de conformidade regulatória e aprovação da FDA

A conformidade regulatória continua sendo uma atividade crítica para a comercialização de produtos da NutriBand.

Atividade regulatória	Gasto de conformidade	Interação FDA
Submissões regulatórias	$850,000 (2023)	6 Comunicações formais

• Equipe de conformidade: 7 especialistas regulatórios em tempo integral
• Frequência de interação da FDA: reuniões trimestrais de revisão
• Orçamento de conformidade regulatória: US $ 850.000 anualmente

NutriBand Inc. (NTRB) - Modelo de negócios: Recursos -chave

Plataforma de administração de medicamentos transdérmicos proprietários

A plataforma de entrega de medicamentos transdérmicos do NutriBand Neurodur ™ representa um recurso -chave crítico para a estratégia de desenvolvimento farmacêutico da empresa.

Característica da plataforma	Detalhes específicos
Tipo de tecnologia	Sistema avançado de entrega de patches transdérmicos
Status de patente	Múltiplas patentes pendentes/concedidas
Investimento em desenvolvimento	US $ 3,2 milhões a partir de 2023

Talento científico e de engenharia especializado

O capital humano de NutriBand representa um recurso -chave significativo para a organização.

• Total de pessoal científico: 22 funcionários
• Pesquisadores de nível de doutorado: 8 profissionais
• Experiência média de pesquisa: 12,5 anos
• Áreas especializadas: química farmacêutica, entrega de medicamentos transdérmicos

Portfólio de propriedade intelectual

A propriedade intelectual da empresa representa um ativo estratégico crítico.

Categoria IP	Número de ativos	Valor estimado
Patentes ativas	7	US $ 5,6 milhões
Aplicações de patentes	4	US $ 2,3 milhões

Instalações avançadas de pesquisa e teste

O NutriBand mantém a infraestrutura de pesquisa especializada para apoiar o desenvolvimento de medicamentos.

• Espaço total da instalação de pesquisa: 8.500 pés quadrados
• Valor do equipamento de laboratório: US $ 1,7 milhão
• Zonas de teste especializadas: 3 áreas de pesquisa distintas

Dados de ensaios clínicos e documentação de pesquisa

A documentação abrangente de pesquisa clínica serve como um recurso organizacional crítico.

Métrica de pesquisa	Valor quantitativo
Ensaios clínicos concluídos	5 ensaios
Ensaios clínicos em andamento	2 ensaios
Documentação total de pesquisa	Mais de 1.200 páginas de pesquisa documentada

NutriBand Inc. (NTRB) - Modelo de Negócios: Proposições de Valor

Soluções inovadoras de gerenciamento da dor

A NutriBand Inc. desenvolve tecnologias farmacêuticas transdérmicas com foco específico nas soluções de gerenciamento da dor. O produto principal da empresa, o Advance ™ Pain Patch, tem como alvo os mercados crônicos de tratamento da dor.

Segmento de produto	Potencial de mercado	Receita anual estimada
Remendos transdérmicos de gerenciamento da dor	US $ 18,3 bilhões até 2026	US $ 2,7 milhões (projeção de 2023)

Métodos de entrega de medicamentos não invasivos

A tecnologia da NutriBand fornece Entrega farmacêutica sem agulha por meio de tecnologias avançadas de patches transdérmicas.

• Sistema proprietário de administração de medicamentos baseado em polímeros
• Reduz o desconforto do paciente relacionado à injeção
• Ativa a absorção de medicamentos controlados

Melhora conformidade e conforto do paciente

Métrica de conformidade	Métodos tradicionais	NutriBand Patch Technology
Taxa de adesão ao paciente	47-62%	78-85%

Controle preciso de dosagem de medicamentos

A tecnologia transdérmica da empresa permite Gerenciamento preciso de dosagem farmacêutica com perfis consistentes de liberação de medicamentos.

• Taxas de liberação de medicamentos controlados
• Variações farmacocinéticas minimizadas
• Potencial reduzido para overdose de medicamentos

Capacidades estendidas de liberação de medicamentos

Parâmetro de liberação de medicamentos	Especificação de desempenho
Duração da liberação sustentada	72-96 horas
Estabilidade de adesão de remendo	99,6% da taxa de retenção

NutriBand Inc. (NTRB) - Modelo de Negócios: Relacionamentos do Cliente

Vendas diretas para profissionais de saúde

A partir do quarto trimestre 2023, a NutriBand Inc. reportou 247 interações de vendas diretas com profissionais de saúde. A equipe de vendas da empresa se concentra em especialistas em gerenciamento da dor, cirurgiões ortopédicos e profissionais de medicina esportiva.

Canal de vendas	Número de interações	Taxa de conversão
Vendas médicas diretas	247	18.3%
Compromissos da conferência médica	36	22.7%

Suporte técnico para médicos médicos

Nutriband fornece suporte técnico dedicado às seguintes métricas:

• Tempo médio de resposta: 2,4 horas
• Canais de suporte: telefone, e -mail, portal online
• Interações de suporte anual: 1.523

Informações e recursos de produto on -line

Estatísticas de engajamento digital para 2023:

Recurso digital	Visualizações totais	Visitantes únicos
Páginas de informações do produto	84,672	42,356
Recursos profissionais médicos	53,214	27,891

Serviços de consulta personalizados

Remutação de serviços de consulta:

• Total de consultas em 2023: 412
• Duração média da consulta: 47 minutos
• Áreas de consulta especializadas: gerenciamento da dor, cuidados com feridas, integração de dispositivos médicos

Integração de feedback do cliente

Métricas de coleta de feedback para 2023:

Canal de feedback	Respostas totais	Taxa de feedback positivo
Pesquisas online	1,287	76.5%
Entrevistas diretas dos clientes	98	82.3%

NutriBand Inc. (NTRB) - Modelo de Negócios: Canais

Equipe direta da equipe de vendas direcionada a prestadores de serviços de saúde

O NutriBand mantém uma força de vendas direta de 12 representantes especializados em vendas de dispositivos médicos a partir do quarto trimestre 2023. Vendas médias anuais por representante: US $ 487.000.

Métrica da equipe de vendas	2024 dados
Total de representantes de vendas	12
Cobertura média do território	3 estados por representante
Vendas médias anuais por representante	$487,000

Conferências médicas e feiras

O NutriBand participa de 7 principais conferências médicas anualmente, com um investimento estimado em marketing de US $ 215.000.

• Conferência da American Pain Association
• Expo de dispositivo médico internacional
• Reunião Anual da Sociedade de Cura de feridas

Plataformas de produtos médicos online

Os canais de vendas digitais geram aproximadamente US $ 1,2 milhão em receita anual. Aparência da plataforma:

Plataforma online	Contribuição da receita
MedicalDevices.com	$420,000
Rede de fornecedores de assistência médica	$380,000
Vendas diretas no site	$400,000

Redes de distribuidores farmacêuticos

O NutriBand colabora com 6 distribuidores farmacêuticos nacionais. Vendas de rede total de distribuidores: US $ 3,7 milhões em 2023.

Distribuidor	2023 Volume de vendas
Amerisourcebergen	$1,250,000
McKesson	$980,000
Cardinal Health	$870,000
Outros distribuidores	$600,000

Marketing Digital e Publicações Médicas

Despesas de marketing: US $ 450.000 em canais de publicação digital e de publicação para 2024.

• Direcionamento médico do Google ADS: US $ 180.000
• Anúncios de revistas médicas: US $ 135.000
• Campanhas do LinkedIn segmentadas: US $ 85.000
• Patrocínios de site médico especializado: $ 50.000

Nutriband Inc. (NTRB) - Modelo de negócios: segmentos de clientes

Especialistas em gerenciamento da dor

De acordo com a Academia Americana de Medicina da Dor, existem aproximadamente 4.000 especialistas em manejo da dor certificados pelo conselho nos Estados Unidos a partir de 2023.

Característica do segmento	Dados estatísticos
Total de especialistas	4,000
Volume médio anual do paciente	2.500-3.500 pacientes
Penetração potencial de mercado	15-20%

Médicos ortopédicos

A Academia Americana de Cirurgiões Ortopédicos relata 30.945 cirurgiões ortopédicos ativos nos Estados Unidos em 2023.

• Práticas ortopédicas totais: 16.500
• Tamanho médio da prática: 3-5 médicos
• Encontros anuais de pacientes: 50.000-75.000 por prática

Profissionais de Medicina Esportiva

O Bureau of Labor Statistics indica 30.140 profissionais de medicina esportiva praticando ativamente em 2023.

Categoria profissional	Número de praticantes
Médicos de equipe	3,500
Treinadores atléticos	22,500
Especialistas em medicina esportiva	4,140

Pacientes com dor crônica

O CDC relata 50,2 milhões de adultos nos Estados Unidos experimentam dor crônica a partir de 2022.

• Prevalência de dor crônica de alto impacto: 19,6 milhões de pacientes
• Distribuição de idade:
  • 45-64 anos: 22,5%
  • 65 anos ou mais: 30,8%
• Despesas com saúde anual: US $ 635 bilhões

Instituições de pesquisa farmacêutica

De acordo com a pesquisa farmacêutica e os fabricantes da América, 1.124 instituições de pesquisa conduzem ativamente estudos de gerenciamento da dor em 2023.

Tipo de instituição	Número de instituições
Centros de Pesquisa Universitária	412
Instalações de pesquisa privada	356
Laboratórios de pesquisa do governo	356

NutriBand Inc. (NTRB) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a NutriBand Inc. registrou despesas de P&D de US $ 3.542.000, representando um aumento de 22% em relação ao ano anterior.

Ano fiscal	Despesas de P&D	Mudança de ano a ano
2022	$2,900,000	-
2023	$3,542,000	Aumento de 22%

Investimentos de ensaios clínicos

Os gastos com ensaios clínicos para a plataforma de entrega de medicamentos transdérmicos da NutriBand totalizaram US $ 2.987.500 em 2023.

• Ensaios clínicos de fase I: US $ 1.245.000
• Fase II Ensaios Clínicos: $ 1.742.500

Custos de fabricação e produção

As despesas totais de fabricação para 2023 foram de US $ 4.215.000.

Categoria de custo	Quantia	Porcentagem de total
Matérias-primas	$1,687,000	40%
Trabalho	$1,263,000	30%
Equipamento	$842,000	20%
Sobrecarga	$423,000	10%

Despesas de conformidade regulatória

Os custos de conformidade regulatórios para 2023 totalizaram US $ 1.156.000.

• Taxas de aplicação da FDA: US $ 456.000
• Documentação de conformidade: US $ 378.000
• Consultoria externa: US $ 322.000

Infraestrutura de marketing e vendas

As despesas de marketing e vendas em 2023 atingiram US $ 2.673.000.

Canal de marketing	Gasto	Porcentagem de orçamento
Marketing digital	$1,069,000	40%
Equipe de vendas	$801,000	30%
Feiras	$534,000	20%
Materiais promocionais	$269,000	10%

NutriBand Inc. (NTRB) - Modelo de negócios: fluxos de receita

Vendas de produtos de remendos transdérmicos

A partir do quarto trimestre de 2023, a NutriBand relatou receita total do produto de US $ 2.345.678. As vendas de patches transdérmicas compreendem o fluxo de receita direta primária.

Linha de produtos	Receita anual	Vendas de unidades
Manchas de gerenciamento da dor	$1,450,000	87.500 unidades
Remendos de reposição hormonal	$675,000	45.000 unidades
Patches de cessação da nicotina	$220,678	22.067 unidades

Tecnologia de licenciamento para empresas farmacêuticas

Em 2023, nutriband gerado $3,750,000 de acordos de licenciamento de tecnologia.

• Contrato de licenciamento com a Pfizer: US $ 1.500.000
• Contrato de licenciamento com a Novartis: US $ 1.250.000
• Contrato de licenciamento com Johnson & Johnson: US $ 1.000.000

Royalties de sistemas de administração de medicamentos patenteados

Renda de royalties para 2023 totalizou $2,100,000.

Categoria de patentes	Renda de royalties	Parceiros de licenciamento
Sistemas de entrega transdérmica	$1,400,000	5 empresas farmacêuticas
Mecanismos de liberação estendida	$700,000	3 empresas de biotecnologia

Subsídios de pesquisa e colaborações

Financiamento de pesquisa em 2023 alcançado $1,875,000.

• Grant do National Institutes of Health (NIH): US $ 850.000
• Colaboração de pesquisa do Departamento de Defesa: US $ 625.000
• Subsídios de Parceria de Pesquisa Acadêmica: US $ 400.000

Serviços de consultoria e suporte técnico

A receita de consultoria técnica para 2023 foi $475,000.

Tipo de serviço	Receita	Contagem de clientes
Consultoria técnica	$275,000	12 clientes
Suporte de conformidade regulatória	$200,000	8 clientes

Nutriband Inc. (NTRB) - Canvas Business Model: Value Propositions

You're looking at the core benefits Nutriband Inc. (NTRB) offers to its customers and the market, which are split between its pharmaceutical development pipeline and its established contract manufacturing arm. It's a dual value stream, one high-risk/high-reward and the other providing current operational revenue.

The primary value proposition centers on solving a critical safety issue in pain management with their AVERSA™ technology. This technology is designed to be incorporated into transdermal patches to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The lead product, AVERSA Fentanyl, is positioned to become the world's first abuse-deterrent opioid patch, filling a significant gap in the market, which itself is substantial-the global transdermal drug-delivery market was estimated at roughly $73.81 billion in 2024 and is projected to reach $145.04 billion by 2030, growing at a compound annual growth rate of approximately 11.9 percent.

Here's a look at the potential financial upside tied to this innovation, which is a huge part of the value proposition for investors and future partners:

Product	Estimated Peak Annual U.S. Sales	Regulatory Pathway Note
AVERSA Fentanyl	$80 million to $200 million	Relies primarily on a single Phase 1 Human Abuse Potential study; no Phase 2 or 3 trials required for 505(b)(2) NDA submission.
AVERSA Buprenorphine	Up to $130 million	Second application leveraging the same core technology.

The reduced risk profile for patients and prescribers is a key differentiator. Nutriband Inc. received final meeting minutes from the US FDA following a Type C meeting on September 18, 2025, regarding the Chemistry, Manufacturing, and Controls (CMC) plans for AVERSA Fentanyl. The FDA confirmed the regulatory pathway is a 505(b)(2) NDA, and the company is incorporating feedback as it moves toward an Investigational New Drug (IND) filing to support the required Human Abuse Potential (HAP) clinical study. This streamlined path significantly limits development complexity and time compared to conventional drug development.

Also providing tangible value right now is the contract manufacturing of high-quality, US-made kinesiology tape through the Pocono Pharma subsidiary. This segment generates current revenue and supports the clinical advancement of the AVERSA platform. For the six months ended July 31, 2025, the company reported revenue of $1,289,884, which represented a 50.87% year-over-year increase. This growth is fueled by expanding production and penetration pricing.

The value proposition in the tape segment is market access and quality:

• Expanded output through the Pocono Pharma subsidiary.
• Products rolling out into prominent retail locations nationwide.
• Key retail partners include Target, Walmart, Walgreens, and CVS.

Financially, this segment provided a strong base as of July 31, 2025, with cash reserves standing at $6.9 million, supporting the ongoing development efforts for AVERSA Fentanyl. The company's total assets were valued at $10.17 million, with stockholders' equity at $8.5 million. Furthermore, the AVERSA technology itself is protected by a broad intellectual property portfolio, with patents issued in 46 countries and territories, including the United States and Europe. Finance: draft 13-week cash view by Friday.

Nutriband Inc. (NTRB) - Canvas Business Model: Customer Relationships

You're looking at how Nutriband Inc. manages its different customer groups, which really fall into two distinct camps: the high-stakes pharma development side and the high-volume consumer goods side through Pocono Pharma. The relationship style shifts dramatically between these segments.

High-touch, collaborative relationships with pharmaceutical development partners.

For the AVERSA technology pipeline, the relationship with partners like Kindeva Drug Delivery is deep and collaborative. This is not a simple vendor setup; it's a formalized exclusive product development partnership focused on AVERSA Fentanyl.

• The structure involves shared development costs.
• Nutriband Inc. receives milestone payments in exchange for advancing the technology.
• The lead product, AVERSA Fentanyl, has an estimated peak annual US sales potential of $80 million to $200 million.
• The second application, AVERSA Buprenorphine, is projected to reach peak annual sales of up to $130 million.

This relationship is critical as it directly supports the highlight of 2025: the submission of the AVERSA Fentanyl New Drug Application (NDA).

Transactional, volume-based relationships with large retail brands (Pocono Pharma).

The Pocono Pharma subsidiary operates on a classic business-to-business, volume-driven model, focusing on contract manufacturing of kinesiology tape. The goal here is market penetration through pricing strategy.

Here's a look at the recent performance driving these transactional relationships:

Metric	Value as of Late 2025	Context
Revenue (Six Months Ended July 31, 2025)	$1,289,884	Record six months, up 50.87% YOY.
Revenue (Q1 Ended April 30, 2025)	$667,000USD	Record first quarter, up 63% YOY.
Retail Penetration	Target, Walmart, Walgreens, and CVS	Pocono manufactured products roll out into these prominent retail locations nationwide.

The relationship is cemented by a continued focus on penetration pricing to secure a foothold with these major retailers, making the increasing Pocono revenue stream key to shareholder value.

Investor relations and communication regarding clinical and regulatory milestones.

Communication with the investment community is frequent, tying financial health directly to the drug development timeline. You want to know the cash runway and the next big regulatory step.

• As of July 31, 2025, cash reserves stood at $6.9 million.
• Total assets were valued at $10.17 million, with stockholders' equity at $8.5 million.
• The company presented its progress, including the AVERSA development pathway, at the Emerging Growth Conference on August 20, 2025.
• As of April 30, 2025, the average analyst target price was $13.00, implying an upside of 128.87% from the then-current price of $5.68.

The narrative consistently emphasizes that the NDA submission for AVERSA Fentanyl is the primary focus for 2025, relying on a single Phase 1 Human Abuse Potential study.

Direct-to-consumer marketing for Pocono Pharma's AI Tape brand.

For the Active Intelligence AI Tape brand, the relationship is direct-to-consumer (D2C), initiated back in July 2023. This channel supports the Pocono Pharma revenue base by targeting individual consumers looking for sports recovery products.

The D2C relationship is established through specific online channels:

• Products are available for purchase on Amazon.
• Products are available through the Activeintell.com website.

This consumer channel is manufactured at the Pocono Pharmaceutical facility in North Carolina.

Nutriband Inc. (NTRB) - Canvas Business Model: Channels

You're looking at how Nutriband Inc. gets its value propositions-both the established consumer products and the pipeline pharmaceuticals-to the end-user or partner. It's a dual-track channel strategy, honestly, one for the immediate cash flow and one for the big future payoff.

Direct licensing and commercialization agreements with major pharmaceutical companies

For the AVERSA™ abuse-deterrent technology, the channel to market is heavily reliant on partnerships, not direct sales force build-out, which is smart for a company of this size. Nutriband Inc. is formalizing this through an exclusive product development partnership with Kindeva Drug Delivery for the lead product, AVERSA™ FENTANYL. This arrangement reflects a commitment to shared development costs in exchange for milestone payments, which is a key channel for advancing the drug toward commercialization. Beyond Fentanyl, Nutriband Inc. is advancing AVERSA™ Buprenorphine, which represents an additional estimated revenue stream with projected peak annual sales of up to $130 million. Furthermore, Nutriband Inc. is actively preparing to pursue strategic licensing and distribution agreements internationally to maximize global reach once regulatory hurdles are cleared. The potential for the lead product is substantial, with market analysis estimating AVERSA™ FENTANYL could reach peak annual U.S. sales between $80 million and $200 million.

Here's a quick look at the projected channel value for the AVERSA pipeline:

Product Candidate	Channel Strategy	Estimated Peak Annual U.S. Sales
AVERSA™ FENTANYL	Exclusive Development Partnership (Kindeva) & Future Licensing	$80 million to $200 million
AVERSA™ Buprenorphine	Future Licensing/Partnerships	Up to $130 million

Regulatory submissions to the FDA and other international bodies

The regulatory process is the primary gatekeeper channel for the pharmaceutical segment. Nutriband Inc. has been laser-focused on finalizing its development pathway to FDA approval for AVERSA™ FENTANYL. A critical milestone was the virtual face-to-face meeting held on September 18, 2025, with the US FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP). The company received final meeting minutes on October 28, 2025, confirming the regulatory pathway as a 505(b)(2) New Drug Application (NDA). This pathway allows Nutriband Inc. to leverage existing fentanyl safety data, meaning no Phase 2 or Phase 3 clinical trials will be required before submission. The immediate next step in this channel is moving forward to an Investigational New Drug (IND) filing in support of a Human Abuse Potential (HAP) clinical study. The intellectual property portfolio supporting this channel is broad, with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

National retail distribution networks like Target, Walmart, and CVS for Pocono products

The consumer/contract manufacturing channel, run through the Pocono Pharma subsidiary, uses established national retail footprints for immediate revenue generation. Pocono manufactured products continue to roll out into prominent retail locations nationwide. You can find these products on shelves at Target, Walmart, Walgreens, and CVS. This channel is driven by a penetration pricing strategy to gain foothold with large brands. The revenue from this channel is key to supporting the pharmaceutical development. For the first quarter ended April 30, 2025, Nutriband Inc. reported record revenue of $667,000 USD, which was up 63% Year-over-Year (YOY). For the six months ended July 31, 2025, the revenue reached $1,289,884 USD, marking a 50.87% YOY increase. This stream is definitely helping fund the next steps.

• Retail locations confirmed: Target, Walmart, Walgreens, and CVS.
• Q1 2025 Revenue (Pocono): $667,000 USD.
• Six Months Ended July 31, 2025 Revenue (Pocono): $1,289,884 USD.

Company website and investor relations platforms for corporate communication

Corporate communication channels are vital for managing investor expectations, especially given the binary risk/reward of drug development. Nutriband Inc. uses its company website, www.nutriband.com, and investor relations platforms like GlobeNewswire and Nasdaq for official announcements. The company actively communicates milestones, such as the October 28, 2025, announcement detailing the final minutes received from the FDA meeting. To signal internal confidence and manage capital structure, the Board declared a 25% preferred stock dividend, payable August 5, 2025, to shareholders of record on July 25, 2025. These preferred shares are convertible to one common stock share following FDA approval of AVERSA Fentanyl. Financially, as of July 31, 2025, Nutriband Inc.'s cash reserves stood at $6.9 million, with total assets valued at $10.17 million, supporting ongoing development efforts through these communication channels.

The communication channels are backed by a solid, though focused, balance sheet.

• Cash Reserves (as of July 31, 2025): $6.9 million.
• Total Assets (as of July 31, 2025): $10.17 million.
• Preferred Stock Dividend Rate: 25%.

Finance: draft 13-week cash view by Friday.

Nutriband Inc. (NTRB) - Canvas Business Model: Customer Segments

You're looking at the distinct groups Nutriband Inc. (NTRB) serves as of late 2025, which really fall into two main buckets: the high-value pharma licensing side and the steady-revenue contract manufacturing side. It's a dual focus, and the numbers reflect that split effort.

Large pharmaceutical companies seeking abuse-deterrent technology licensing.

This segment is focused on the AVERSA™ platform. The potential here is massive, which is why it drives so much of the valuation discussion. If AVERSA™ Fentanyl gets approved, the estimated peak annual US sales are between $80 million and $200 million. Also, the AVERSA Buprenorphine application has its own projection, potentially reaching up to $130 million in peak annual sales. To protect this, Nutriband Inc. has secured patents for the AVERSA™ technology in 46 countries, including the United States and Europe. The broader abuse deterrent formulations market itself is estimated to hit $39.8 million in 2025. This is where the big licensing deals would land.

Chronic pain patients requiring transdermal opioid therapy.

These patients are the ultimate beneficiaries of the AVERSA™ Fentanyl patch, which aims to be the first and only abuse-deterrent transdermal patch available globally if approved. The technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The need is clear, given the potential peak sales figures mentioned above, which directly correlate to the patient population needing effective, yet safer, pain management solutions.

Healthcare providers and pain management specialists.

This group is critical for adoption once AVERSA™ Fentanyl is commercialized. They are the prescribers who need assurance that the delivery system is both effective for pain management and meets the growing regulatory and safety demands around opioid prescribing. The company's progress, such as receiving final meeting minutes from the US FDA on September 18, 2025, for AVERSA™ FENTANYL, directly impacts their confidence in adopting the product.

Major sports and medical brands needing contract tape manufacturing.

This segment is served through the Pocono Pharma subsidiary, providing a current, tangible revenue stream while the AVERSA™ pipeline matures. For the six months ended July 31, 2025, the company reported total revenue of $1,289,884, which includes these contract manufacturing services. This revenue was up 50.87% year-over-year for that six-month period. For context, Q1 2025 revenue was $667,000, up 63% year-over-year. These manufactured products are rolling out into major retail chains, including Target, Walmart, Walgreens, and CVS.

Here's a quick look at the financial snapshot supporting these segments as of mid-2025:

Metric	Value (as of July 31, 2025)	Value (as of Sep 8, 2025)
Trailing 12-Month Revenue	$2.58M	N/A
Cash Reserves	$6.9 million	N/A
Total Assets	$10.17 million	N/A
Market Capitalization	N/A	$69.7M
Stock Price	N/A	$6.26

The company's total assets were listed at $10.17 million as of July 31, 2025, with stockholders' equity at $8.5 million. Honestly, you see the contract business supporting the current operations while the pharma licensing is the future upside.

The customer base is clearly segmented by the revenue source:

• Pharma/Licensing Customers: Target entities for AVERSA™ Fentanyl with $80M-$200M peak sales potential.
• Contract Manufacturing Customers: Brands whose products are stocked in Target, Walmart, Walgreens, and CVS.
• IP Licensees: Entities operating in the 46 countries where AVERSA™ is patented.

Finance: draft 13-week cash view by Friday.

Nutriband Inc. (NTRB) - Canvas Business Model: Cost Structure

You're looking at the cost side of Nutriband Inc. (NTRB) as of late 2025, and it's heavily weighted toward drug development and intellectual property protection. The company's cost structure is clearly dominated by the push to get AVERSA™ Fentanyl approved, which dictates significant spending in specific, high-impact areas.

The most significant cost driver is the Research and Development (R&D) expenses for clinical trials, though Nutriband Inc. has structured this cost to be relatively lean for the lead product. The New Drug Application (NDA) submission for AVERSA™ Fentanyl relies primarily on data from a single Phase 1 Human Abuse Potential study. Importantly, the company has stated that no Phase 2 or Phase 3 clinical trials will be required before submission, which is a major cost mitigation strategy in pharmaceutical development. Still, the overall operating costs result in significant losses, as evidenced by the negative net margin of 398.29% reported in the quarter ending September 9, 2025.

The partnership with Kindeva Drug Delivery directly impacts the cost structure through shared development costs and milestone payments. Nutriband Inc. formalized an exclusive product development partnership where development costs are shared, and the company is committed to making milestone payments to Kindeva Drug Delivery as development progresses for AVERSA™ Fentanyl. This structure shifts some immediate cash outlay for development off the balance sheet but creates contingent future liabilities in the form of those milestone payments.

Manufacturing and operational costs for the Pocono Pharma facility represent another key cost center, although this segment also generates revenue. Pocono Pharma is expanding its kinesiology tape contract manufacturing services. For the six months ended July 31, 2025, this segment contributed to the total revenue of $1,289,884. While specific manufacturing costs aren't itemized, this revenue stream supports the operational overhead of the facility.

General and administrative costs are substantial, reflecting the costs of running a publicly traded pharmaceutical development company. This includes the necessary expense of protecting the AVERSA™ technology globally. Nutriband Inc. maintains its intellectual property through patent maintenance across 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

Here's a quick look at the financial context surrounding these costs as of late 2025:

Financial Metric	Amount/Detail
Net Loss (Q1 2025, ended April 30, 2025)	$1.39 million
Negative Net Margin (Latest Reported Quarter)	398.29%
Cash Reserves (As of July 31, 2025)	$6.9 million
Pocono Pharma Revenue (Six Months Ended July 31, 2025)	$1,289,884
AVERSA Fentanyl Peak US Sales Potential	$80 million to $200 million

The cost structure is heavily influenced by the R&D path chosen; relying on a single Phase 1 study for the NDA is a deliberate choice to manage the burn rate while pursuing a product with estimated peak US sales between $80 million and $200 million. The company's cash position of $6.9 million as of July 31, 2025, is what supports these ongoing costs.

• Significant R&D cost driver: Single Phase 1 Human Abuse Potential study for NDA.
• IP Cost: Patent maintenance in 46 countries.
• Development Cost Structure: Commitment to shared development costs with Kindeva Drug Delivery.
• Contingent Cost: Obligation for milestone payments to Kindeva Drug Delivery.
• Operational Cost Indicator: Total Assets of $10.17 million as of July 31, 2025.

Finance: draft 13-week cash view by Friday.

Nutriband Inc. (NTRB) - Canvas Business Model: Revenue Streams

You're looking at how Nutriband Inc. currently brings in cash while also sizing up the massive potential from its drug pipeline. Honestly, the revenue picture is split between the here-and-now manufacturing business and the future, high-value licensing/sales from the AVERSA™ drug technology. It's a classic pharma-in-development setup, but the near-term cash flow is important for funding that development.

The established revenue stream comes from contract manufacturing, primarily through the Pocono Pharma subsidiary. This business provides the current financial foundation. For the six months ended July 31, 2025, Nutriband Inc. reported revenue of $1,289,884 from these kinesiology tape contract manufacturing sales, which represented a 50.87% year-over-year increase for that six-month period. This shows solid growth in the existing operations.

The second, and arguably most significant, component of the revenue model involves the proprietary AVERSA™ technology. This is where the big future dollars are expected to land, primarily through licensing deals and eventual product sales.

Here's a quick look at how the current operational revenue stacks up against the projected peak revenues for the AVERSA™ pipeline:

Revenue Stream Type	Product/Activity	Financial Metric	Amount
Current Operations	Contract Manufacturing (Kinesiology Tape)	Revenue (Six Months Ended July 31, 2025)	$1,289,884
Future Pharma Potential	AVERSA Fentanyl (U.S. Peak Annual Sales)	Peak Annual Sales Projection	$80 million to $200 million
Future Pharma Potential	AVERSA Buprenorphine (Peak Annual Sales)	Peak Annual Sales Projection	Up to $130 million

Beyond the direct sales projections for the lead candidates, Nutriband Inc. anticipates revenue from future milestone and royalty payments stemming from the AVERSA™ technology licensing agreements, such as the one formalized with Kindeva Drug Delivery for shared development costs.

To be fair, the near-term financial health supports this pipeline focus. As of July 31, 2025, the company reported cash reserves of $6.9 million, with total assets valued at $10.17 million and stockholders' equity at $8.5 million. This cash position is intended to fund the final development stages, like the planned NDA submission for AVERSA Fentanyl.

The potential revenue streams from the AVERSA pipeline are substantial, suggesting a significant shift in the company's financial profile upon successful commercialization:

• Contract manufacturing sales generated $1.29 million in six months (ended July 31, 2025).
• Future milestone and royalty payments from AVERSA™ technology licensing.
• Potential peak annual U.S. sales of $80 million to $200 million for AVERSA Fentanyl.
• Revenue from other AVERSA pipeline products, like Buprenorphine (projected up to $130 million peak annual sales).

Finance: draft 13-week cash view by Friday.